Condition (MeSH)
Prolactinoma
ClinicalTrials.gov lists 28 trials for Prolactinoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
28 of the 28 trials are tagged with Prolactinoma itself; the rest are tagged with a narrower condition beneath it.
When did Prolactinoma trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2021 | 1 |
| 2019 | 2 |
| 2018 | 3 |
| 2016 | 3 |
| 2015 | 1 |
| 2014 | 1 |
| 2011 | 1 |
| 2010 | 3 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Prolactinoma trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
| Not applicable | 6 |
| Observational | 13 |
How many Prolactinoma trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 2 |
| Completed | 8 |
| Terminated | 2 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Prolactinoma trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| National Cancer Institute (NCI) | 1 |
Which drugs are being tested for Prolactinoma? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ropinirole | 1 |
| LAPATINIB | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cabergoline Pill | 6 |
| dopamine agonist treatment | 1 |
| clomiphen citrate | 1 |
| SOC: Temozolomide | 1 |
| Dexamethasone/Dexamethasone acetate | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Prolactinoma trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Transaminitis | 1 | 1 |
Which publications cover Prolactinoma? (34)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. | The Journal of clinical endocrinology and metabolism | 2024 | Yes |
| Muscle function, exercise capacity, physical activity level and cardiovascular disease risk factor knowledge in patients with prolactinoma. | Endocrine | 2024 | Yes |
| Prolactin in headache and migraine: A systematic review of clinical studies. | Cephalalgia : an international journal of headache | 2023 | Yes |
| MEN4, the MEN1 Mimicker: A Case Series of three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations. | The Journal of clinical endocrinology and metabolism | 2022 | Yes |
| <sup>11</sup>C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. | Pituitary | 2022 | Yes |
Showing 5 of 34 publications.
Prevalence (15)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Prolactinoma | Point prevalence | 1-5 / 10 000 | United Kingdom | GB | Exact |
| Prolactinoma | Point prevalence | 1-5 / 10 000 | United Kingdom | GB | Exact |
| Prolactinoma | Point prevalence | 1-5 / 10 000 | United Kingdom | GB | Unspecified |
| Prolactinoma | Annual incidence | 1-9 / 100 000 | Malta | Not stated | Exact |
| Prolactinoma | Annual incidence | 1-9 / 100 000 | Malta | Not stated | Unspecified |
Showing 5 of 15 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Prolactinoma | 2965 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Prolactinoma | 2965 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.